• Email
  • Help


The marketing authorisation for EchoGen has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 22/05/2001 .

Authorisation details

Product details

Product details for EchoGen
Agency product numberEMEA/H/C/000149
Active substance


International non-proprietary name (INN) or common name


Therapeutic area Echocardiography
Anatomical therapeutic chemical (ATC) code V08DA

Publication details

Publication details for EchoGen
Marketing-authorisation holder

Sonus Pharmaceuticals Ltd.

Date of issue of marketing authorisation valid throughout the European Union17/07/1998

Contact address:

Sonus Pharmaceuticals Ltd.
Knyvett House
The Causeway
Staines, Middlesex TW18 3BA
United Kingdom

Product information

Product information

22/01/2001  EchoGen -EMEA/H/C/000149


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Contrast media

Therapeutic indication

EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.

EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated

Initial marketing-authorisation documents

Name Language First published Last updated


This medicine is now withdrawn from use in the European Union

More information on Echogen